CN112839947A - 用于治疗结直肠癌的tlr7激动剂及其药物组合 - Google Patents

用于治疗结直肠癌的tlr7激动剂及其药物组合 Download PDF

Info

Publication number
CN112839947A
CN112839947A CN201980067200.XA CN201980067200A CN112839947A CN 112839947 A CN112839947 A CN 112839947A CN 201980067200 A CN201980067200 A CN 201980067200A CN 112839947 A CN112839947 A CN 112839947A
Authority
CN
China
Prior art keywords
pyrrolo
pyrimidin
butoxy
amine
benzyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201980067200.XA
Other languages
English (en)
Other versions
CN112839947B (zh
Inventor
徐宏江
张旻澄
张颖
宋伟
杨玲
张喜全
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Priority to CN202310002030.5A priority Critical patent/CN116098905A/zh
Publication of CN112839947A publication Critical patent/CN112839947A/zh
Application granted granted Critical
Publication of CN112839947B publication Critical patent/CN112839947B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

治疗结直肠癌的作为Toll样受体7(TLR7)激动剂的式I化合物或其药学上可接受的盐，用于治疗结直肠癌的包括TLR7激动剂和酪氨酸激酶抑制剂的药物组合，以及式I化合物或其药学上可接受的盐和所述药物组合在治疗结直肠癌中的用途。(I)

Description

PCT国内申请，说明书已公开。

Claims (15)

  1. PCT国内申请，权利要求书已公开。
CN201980067200.XA 2018-10-12 2019-10-12 用于治疗结直肠癌的tlr7激动剂及其药物组合 Active CN112839947B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202310002030.5A CN116098905A (zh) 2018-10-12 2019-10-12 用于治疗结直肠癌的tlr7激动剂及其药物组合

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2018111878376 2018-10-12
CN201811187837 2018-10-12
PCT/CN2019/110824 WO2020074006A1 (zh) 2018-10-12 2019-10-12 用于治疗结直肠癌的tlr7激动剂及其药物组合

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202310002030.5A Division CN116098905A (zh) 2018-10-12 2019-10-12 用于治疗结直肠癌的tlr7激动剂及其药物组合

Publications (2)

Publication Number Publication Date
CN112839947A true CN112839947A (zh) 2021-05-25
CN112839947B CN112839947B (zh) 2023-01-24

Family

ID=70164488

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202310002030.5A Pending CN116098905A (zh) 2018-10-12 2019-10-12 用于治疗结直肠癌的tlr7激动剂及其药物组合
CN201980067200.XA Active CN112839947B (zh) 2018-10-12 2019-10-12 用于治疗结直肠癌的tlr7激动剂及其药物组合

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202310002030.5A Pending CN116098905A (zh) 2018-10-12 2019-10-12 用于治疗结直肠癌的tlr7激动剂及其药物组合

Country Status (6)

Country Link
US (1) US20220235053A1 (zh)
EP (1) EP3865483A4 (zh)
CN (2) CN116098905A (zh)
AU (1) AU2019357451A1 (zh)
CA (1) CA3116137A1 (zh)
WO (1) WO2020074006A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115119508B (zh) * 2021-01-20 2024-05-24 上海维申医药有限公司 大环tlr7激动剂、其制备方法、药物组合物及其用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016023511A1 (zh) * 2014-08-15 2016-02-18 正大天晴药业集团股份有限公司 作为tlr7激动剂的吡咯并嘧啶化合物
WO2017076346A1 (zh) * 2015-11-05 2017-05-11 正大天晴药业集团股份有限公司 作为tlr7激动剂的7-(噻唑-5-基)吡咯并嘧啶化合物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016023511A1 (zh) * 2014-08-15 2016-02-18 正大天晴药业集团股份有限公司 作为tlr7激动剂的吡咯并嘧啶化合物
WO2017076346A1 (zh) * 2015-11-05 2017-05-11 正大天晴药业集团股份有限公司 作为tlr7激动剂的7-(噻唑-5-基)吡咯并嘧啶化合物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GUOSHUANG SHEN ET AL: "Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development", 《JOURNAL OF HEMATOLOGY & ONCOLOGY》 *
REYHANEH MORADI-MARJANEH ET AL,: "Toll like receptor signaling pathway as a potential therapeutic target in colorectal cancer", 《J.CELL PHYSIOL》 *

Also Published As

Publication number Publication date
AU2019357451A1 (en) 2021-06-03
WO2020074006A1 (zh) 2020-04-16
CN112839947B (zh) 2023-01-24
US20220235053A1 (en) 2022-07-28
EP3865483A1 (en) 2021-08-18
EP3865483A4 (en) 2022-06-08
CN116098905A (zh) 2023-05-12
CA3116137A1 (en) 2020-04-16

Similar Documents

Publication Publication Date Title
CN110382499B (zh) Fgfr抑制剂及其应用
US20210214361A1 (en) Aurora kinase inhibitors for inhibiting mitotic progression
TWI726363B (zh) Fak/alk/ros1抑制劑與egfr抑制劑的組合治療癌症的方法
WO2001083456A1 (fr) Derives d'heteroaryle condenses
US20220363648A1 (en) Glucose Uptake Inhibitors
TW201915004A (zh) 噻吩並嘧啶類化合物、其製備方法、藥用組合物及其應用
TW202304914A (zh) 經取代之四環羧酸、其類似物及使用其之方法
CN112839947B (zh) 用于治疗结直肠癌的tlr7激动剂及其药物组合
US20210251991A1 (en) Substituted 2,2'-bipyrimidinyl compounds, analogues thereof, and methods using same
CN112105620A (zh) 用于治疗肺癌的tlr7激动剂及其药物组合
KR20210063332A (ko) 퀴놀린카르복사미드 유도체를 사용하는 암 병용 요법
AU2019272478B2 (en) TLR7 agonist and pharmaceutical combination thereof for treating lung cancer
TW202132285A (zh) 經取代異吲哚啉基2,2’-聯嘧啶基化合物、其類似物及使用其之方法
CN114430681A (zh) 使用egfr和cdk4/6抑制剂的组合治疗egfr突变相关的癌症
WO2020006724A1 (zh) 一种靶向降解fak蛋白的化合物及其应用
WO2021058021A1 (zh) 包含tlr7激动剂的药物组合
CN112625025B (zh) 吡啶基取代的喹啉类衍生物及其制备方法和用途
US11795179B2 (en) Discovery of imidazothiazole- and imidazooxazole-based selective HER4 kinase inhibitors as potential anticancer agents
CN114105977B (zh) 雌激素受体调节剂化合物及其用途
CN116261455A (zh) 一种药物组合物及其在治疗癌症中的用途
CN113164487A (zh) 磷酸二酯酶抑制剂

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant